Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.16 (market cap $140.85M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 34.6× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KOLD | TVTX | |
|---|---|---|
Market Cap | $140.85M | $4.88B |
Volume | 4,297,516 | 1,668,577 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $67.52 |
52-Week Low | $13.58 | $26.79 |
Typical Hold Time | 10 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $23.85, down 5.06% over the past 24 hours amid bearish technical signals. The stock shows significant selling pressure with 16 sell signals versus 1 buy signal across technical indicators. Natural gas market fundamentals remain challenging with record-high U.S. production reported by the EIA in July 2026, while geopolitical tensions in the Middle East create volatility in energy markets.
The outlook remains cautious as technical indicators point to continued downward momentum. Investment opportunities exist for contrarian investors given the oversold RSI reading, but risks include persistent natural gas price weakness and high production levels that may pressure energy sector performance in the near term.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
